LONDON (ShareCast) - (Sharecast News) - Pharmaceutical group N4 Pharma has completed the first phase of Covid-19 proof of concept work for Nuvec, the group's novel delivery system for cancer treatments and vaccines.
N4 Pharma's proof of concept work, carried out within the expected timeframe, resulted in plasmid DNA being successfully amplified to produce sufficient material for the rest of the project.

Evotec, which N4 hired to undertake the project, also used this batch of the plasmid DNA as a positive control for its studies.

The AIM-listed group stated that Evotec would now move on to the second phase of the project in the first week of June, starting the in-vitro testing of Nuvec. This phase is expected to last approximately ten weeks.

N4 said: "The third phase of the in-vivo protein expression testing will be to undertake an initial pre in-vivo study to demonstrate expression of the spike protein in target cells in a murine target.

"Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work."

As of 0945 BST, N4 shares were up 1.90% at 5.30p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE